GT Biopharma Inc. (NASDAQ: GTBP) has dosed the first patient in a Phase 1 trial evaluating GTB-5550, a B7-H3-targeted natural ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE